TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. TME Pharma’s mission is to improve treatment outcomes for patients with cancer where TME significantly limits survival. The lead compound NOX-A12 acts in two distinct mechanisms of action, presenting great potential for developing this asset in various oncology indications. Currently, TME Pharma is focused on brain cancer (glioblastoma, GBM), with promising topline clinical results.NOXXON's Spiegelmer® platform has generated a proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with KEYTRUDA® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON’s pipeline also contains NOX-E36, which targets other tumor microenvironment targets implicated in cancer spread and immune privilege of tumors.

TME Pharma

Domain Not Resolving

Microsoft Exchange Online

Office 365 Mail

Cloudflare Hosting

Microsoft Azure DNS

YouTube

IONOS DNS

Information Technology

Christian Mihm

Operations

Dr. Diana Beyer

Finance and Administration

Ewelina Staniuk

Business Management

Aram Mangasarian

Engineering

Stefan Vonhoff

Axel Polack

Olivier Litzka

Jarl Ulf Jungnelius

Frank Morich

VP Chemistry & Manufacturing

Walter Wenninger

Chairman of the Board

Europe Health Care Companies (Top 10K)

Europe Companies With Less Than $50M in Revenue (Top 10K)

Biotechnology Public Companies With Less Than $50M in Revenue

Pharmaceutical Companies With Less Than $50M in Revenue (Top 10K)

TME Pharma is a biopharmaceutical company, develops biostable aptamers and substances based on mirror image nucleic acids. Its Spiegelmer is a mirror image oligonucleotide therapeutic for the pharmacologically relevant target. The company has a strategic alliance with Pfizer, Inc. NOXXON Pharma AG was founded in 1997 and is based in Berlin, Germany.

German Federal Ministry of Education and Research

Grant - TME Pharma

Post-IPO Equity - TME Pharma

Atlas Special Opportunities

Post-IPO Debt - TME Pharma

Acuitas Investments

Berlin

Germany

Europe

TME Pharma Announces Poster Presentation by U.S. National Cancer Institute on CXCL12 Inhibition by NOX-A12 in Glioblastoma at 2024 SNO Annual Meeting

TME Pharma N.V. Provides Clinical Update

TME Pharma Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma Provides Results of Third Exercise of Warrants Z

TME Pharma Announces Convocation of an Extraordinary General Meeting of Shareholders

TME Pharma Provides Update on Resources Allocated to the Liquidity Contract With Invest Securities

TME Pharma Announces Strategic Plan to Externalize and Monetize Second Clinical Stage Asset NOX-E36

An RNA aptamer targeting CXCL12 for enhancing the effectiveness of anti-cancer treatments in glioblastoma and pancreatic cancer without significant side effects.

An RNA aptamer targeting CCL2 and related chemokines, intended for use in oncology to improve immune response against tumors by modulating the tumor microenvironment.

A study evaluating NOX-A12 in combination with radiotherapy and other treatments in glioblastoma patients resistant to standard chemotherapy.

Clinical trials in collaboration with MSD/Merck to evaluate NOX-A12 in combination with pembrolizumab and chemotherapy in pancreatic cancer.

TME Pharma seeks partners to advance its portfolio, focusing on collaborations with pharmaceutical leaders, academic investigators, and research organizations.

India

Asia

United Kingdom

HTML5

Apache Server

Google Fonts

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.

TME Pharma N.V.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	a8e2f4bf
crunchbase profile	general	Nov 25, 2024 11:37 AM	c7264e5c
li profile	general	Feb 2, 2024 2:19 PM	02232cc2
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	3682464e
peers	general	Feb 2, 2024 2:19 PM	2c6d4230
news basic	general
bundesanzeiger	filings	Feb 12, 2024 3:18 PM	72de36ed
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:TMEPHARMA

TME Pharma N.V.

Last Close

0.15

25/11 09:23

Market Cap

6.05M

Beta: -

Volume Today

744.63K

Avg: -